619 West 54th Street, 8th Floor
Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality.1 HiberCell seeks to change that. As “the dormancy company,” we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.
5 articles with HiberCell
5/26/2021Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars.
12/4/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer
HiberCell, a biotechnology company dedicated to overcoming foundational barriers that prevent patients from living longer, cancer-free lives, announced the appointment of Joseph Talamo as chief financial officer and the promotion of Ari Nowacek, M.D., Ph.D., to chief business officer.
- Imprime PGG, a novel immune activator, has undergone rigorous Phase II testing for the treatment of metastatic breast cancer - Biothera president and chief scientific officer, Jeremy R. Graff, Ph.D., will assume the role of chief development officer at HiberCell
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.